Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 3, 2023

Primary Completion Date

May 1, 2025

Study Completion Date

July 1, 2025

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

Trilaciclib

trilaciclib 240mg/m2 ivgtt d1 Q3w; anti-PD-1 antibody 200mg ivgtt d1 Q3w; Paclitaxel-albumin 250mg/m2 ivgtt d1 Q3w or 125mg/m2 ivgtt d1,d8 Q3w; carboplatin AUC=5 ivgtt d1 Q3w; Review every 2 cycles until the best efficacy or intolerable toxicity, usually 6-8 cycles;

Trial Locations (1)

100021

RECRUITING

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Beijing

All Listed Sponsors
lead

QIAO LI

OTHER